Etodolac is a medication with the active ingredient etodolac, which is also known by the brand names Lodine and Lodine XL. It is used to relieve pain and inflammation caused by conditions such as arthritis. Etodolac works by reducing the levels of certain chemicals in the body that cause pain and swelling.
A pack of Etodolac can cost anywhere between £0.53 and £1.87. The exact price depends on pack measurements and active ingredient density (30 or 360 mg).
Etodolac is the generic name of a nonsteroidal anti-inflammatory drug (NSAID). It is used to treat mild to moderate pain, inflammation, and arthritis symptoms. It belongs to the class of drugs called pyranocarboxylic acids and is commercially available in various brand names.
Etodolac works by inhibiting the enzyme cyclooxygenase (COX). It reduces the synthesis of prostaglandins, which are chemicals responsible for pain, fever, and inflammation. COX-1 and COX-2 inhibition contribute to its therapeutic and adverse effects.
Etodolac is available in multiple dosage forms, including immediate-release tablets, extended-release tablets, and capsules. Dosage strength typically ranges from 200 mg to 600 mg, allowing for flexible dosing to meet individual patient needs.
Etodolac is primarily indicated for the management of osteoarthritis and rheumatoid arthritis. It is also prescribed for the relief of mild to moderate acute pain caused by various conditions, such as soft tissue injuries and postoperative pain.
After oral administration, Etodolac is well absorbed, with peak plasma concentrations occurring within 1 to 2 hours for immediate-release forms. Extended-release forms maintain therapeutic levels longer. The drug is extensively metabolized in the liver and excreted primarily through urine.
Dosing for osteoarthritis typically starts at 300 mg twice daily or 400 mg once daily for immediate-release forms. For extended-release forms, 600 mg once daily is common. Adjustments are based on patient response and tolerability. Maximum recommended dose is 1200 mg per day.
Etodolac may interact with other medications, including anticoagulants like warfarin, antiplatelet agents like aspirin, and other NSAIDs. Concomitant use can increase the risk of gastrointestinal bleeding. Caution is advised when used with antihypertensive agents, as NSAIDs can reduce their efficacy.
Common adverse reactions to Etodolac include gastrointestinal issues such as dyspepsia, nausea, and abdominal pain. Cardiovascular risks include hypertension and edema. Hepatotoxicity and nephrotoxicity, though less common, are serious adverse reactions and require monitoring.
Patients on long-term Etodolac therapy should be regularly monitored for renal and hepatic function. Blood pressure should also be monitored due to the risk of hypertension. Complete blood count (CBC) is recommended to detect potential hematologic side effects.
Etodolac is contraindicated in patients with known hypersensitivity to the drug, history of asthma or allergic reactions to NSAIDs, active gastrointestinal bleeding, and severe renal impairment. It should be avoided during late pregnancy due to potential harm to the fetus.
Etodolac should be taken with food or a full glass of water to minimize gastrointestinal distress. Extended-release tablets should not be crushed or chewed. Patients are advised to adhere to prescribed dosing schedules and not to exceed recommended dosages.
Store Etodolac at room temperature, away from moisture and light. Keep the medication in its original container and out of the reach of children. Do not store in the bathroom, and dispose of any expired or unused medication properly.
Etodolac is classified as a Category C drug for pregnant women. Animal studies have shown potential risks, but there are no adequate studies in pregnant women. Use during pregnancy should be considered only if the potential benefit justifies the potential risk to the fetus.
It is unknown whether Etodolac is excreted in human milk. Due to potential adverse effects on nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the medication to the mother.
The safety and efficacy of Etodolac in pediatric patients have not been established. Use in children under the age of 18 is not recommended unless explicitly prescribed by a healthcare provider based on a thorough risk-benefit analysis.
Geriatric patients may be more susceptible to adverse reactions, particularly gastrointestinal bleeding and renal impairment. Dose selection should be cautious, usually starting at the lower end of the dosing range, and renal function assessment is advisable.
If a dose is missed, take it as soon as remembered unless it’s close to the time for the next dose. Do not double the dose to catch up. Stick to the regular dosing schedule to maintain the drug’s effectiveness.
In case of an overdose, seek immediate medical attention. Symptoms of overdose may include severe nausea, vomiting, stomach pain, drowsiness, and gastrointestinal bleeding. Supportive and symptomatic treatment in a healthcare setting is essential.
Regular liver function tests are recommended for patients on long-term Etodolac therapy. Elevated liver enzymes may necessitate dosage adjustments or discontinuation. Monitoring helps prevent serious hepatotoxicity.
Renal function should be assessed regularly, especially in patients with pre-existing kidney conditions. Etodolac can cause renal impairment and should be used cautiously in patients with a known history of renal diseases.
Etodolac should be discontinued prior to elective surgery to reduce the risk of excessive bleeding. Physicians should be informed of Etodolac use before any scheduled surgical procedures to manage perioperative care optimally.
Etodolac can interfere with certain laboratory tests, including liver function tests and coagulation profiles. It is essential to inform the laboratory personnel and healthcare providers about Etodolac therapy for accurate test interpretation.
Patients are advised to limit or avoid alcohol consumption while taking Etodolac. Alcohol can increase the risk of gastrointestinal bleeding and other adverse effects, particularly when combined with NSAID therapy.
Educational leaflets and materials about NSAID use, potential side effects, and monitoring requirements should be provided to patients to enhance understanding and adherence to therapy. Proper education can help optimize therapeutic outcomes.